Generic Name and Formulations:
Ursodiol 250mg; tabs.
Indications for URSO:
Primary biliary cirrhosis.
Take with food. 13–15mg/kg per day in 2–4 divided doses.
Complete biliary obstruction.
Variceal bleeding, hepatic encephalopathy, ascites, and/or need for an urgent liver transplant: give appropriate specific treatment. Monitor liver function and bilirubin monthly for 3 months after starting therapy, then every 6 months thereafter; consider discontinuing if levels increase significantly with history of stable liver function. Monitor and maintain bile flow. Pregnancy (Cat.B). Nursing mothers.
Reduced absorption with bile acid sequestrants (eg, cholestyramine, colestipol), and aluminum-containing antacids. Estrogens, oral contraceptives, clofibrate, other lipid-lowering drugs may reduce effectiveness of ursodiol by increasing hepatic cholesterol secretion.
Abdominal discomfort or pain, alopecia, diarrhea, nausea, pruritus, rash, leukopenia, elevated creatinine or blood glucose, thrombocytopenia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy